H. Pylori Infection Clinical Trial
Official title:
Immediate Detection of Helicobacter Infection With a New Electrochemical System
Helicobacter pylori-infection (H. pylori) affects about fifty percent of the general population and is associated with peptic ulcer disease, non-cardia gastric adenocarcinoma and gastric lymphoma. Currently, diagnostic methods include breath tests, serology, stool antigen tests, histology or the Helicobacter urease test (HUT). The aim of our study is to access the clinical reliability of a new, electrochemical device for rapid H. pylori detection.
The newly developed electrochemical device for H. pylori detection consists of a working and reference electrode between which a biopsy sample is administered. Afterwards, acquired voltage-values could be analysed for characteristics typical for H. pylori infection (ammonia). According to Sydney classification, biopsies are taken from gastric antrum and corpus for electrochemical H. pylori detection, HUT and immunohistochemistry (IHC). HUT results are evaluated after 24 hours. Furthermore, every patient will receive 13C-urea breath test. IHC is designated as the gold standard of H. pylori diagnosis. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06045494 -
The Efficacy of Treatment for Helicobacter Pylori Infection in Preschooler by Yoghurt With LG21
|
N/A | |
Not yet recruiting |
NCT01449500 -
Supplementation With L. Reuteri in H. Pylori Infected Adults
|
N/A | |
Not yet recruiting |
NCT05387005 -
Screening Strategy for Gastric Cancer Prevention
|
N/A | |
Not yet recruiting |
NCT02761005 -
Eradication of H. Pylori Therapy Individualized by the Mutation of 23S rRNA of H. Pylori
|
Phase 2 | |
Recruiting |
NCT03142620 -
Effect of Vitamin D on Drug Resistant Helicobacter Pylori (HP) Eradication Study
|
Phase 3 | |
Withdrawn |
NCT02090738 -
A Randomized, Open-label Study on Helicobacter Pylori Eradication With Standard Triple Regimen Plus Acetazolamide
|
Phase 2 | |
Recruiting |
NCT01335334 -
H. Pylori Eradication Using Pyklear in Adults in El Paso, Texas: a Pilot Study
|
Phase 4 | |
Recruiting |
NCT05544396 -
Study on the Probiotics Regulating miRNA in H. Pylori-induced Wnt/β-catenin Gastric Carcinogenesis.
|
N/A | |
Recruiting |
NCT04713670 -
Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection
|
Phase 4 | |
Recruiting |
NCT06045832 -
Oral Helicobacter Pylori Eradication
|
N/A | |
Completed |
NCT05453994 -
Bismuth for PCAB-based H. Pylori Eradication
|
||
Recruiting |
NCT02328131 -
European Registry on the Management of Helicobacter Pylori Infection
|
||
Completed |
NCT00197457 -
Pepsinogens as the Early Marker of H. Pylori Eradication
|
Phase 2 | |
Not yet recruiting |
NCT06412640 -
Optimization of Keverprazan-amoxicilli Dual Therapy for Helicobacter Pylori
|
Phase 4 | |
Completed |
NCT04036838 -
ARJ C13 Urea Breath Test System
|
Phase 2 | |
Completed |
NCT06050824 -
A Comparative Study Between Concomitant Versus Load Therapy in Eradication of Helicobacter Pylori Infection
|
Phase 4 | |
Completed |
NCT02767479 -
Comparison of Rabeprazole and Esomperazole for the Eradication of H. Pylori
|
Phase 3 | |
Completed |
NCT01505127 -
Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori
|
Phase 3 | |
Recruiting |
NCT05176821 -
Eradication Efficacy and Safety of Two Rescue Treatments for Helicobacter Pylori Infection
|
N/A | |
Completed |
NCT05002595 -
H. Pylori Treatment Between Modified Quadruple Regimen and Tailored Therapy
|